|Mr. Lloyd Mitchell Segal||President, CEO & Director||913.39k||N/A||1964|
|Dr. Michael Zinda Ph.D.||Executive VP & Chief Scientific Officer||641.53k||N/A||1971|
|Dr. Maria Koehler M.D., Ph.D.||Executive VP & Chief Medical Officer||682.8k||N/A||1957|
|Dr. Daniel Durocher Ph.D.||Co-Founder||N/A||N/A||N/A|
|Dr. Frank Sicheri Ph.D.||Co-Founder||N/A||N/A||N/A|
|Dr. Agnel Sfeir Ph.D.||Co-Founder||N/A||N/A||N/A|
|Mr. Steve Forte||Executive VP & CFO||608.52k||N/A||1979|
|Mr. Daniel Belanger||Executive Vice President of Human Resource||N/A||N/A||N/A|
|Mr. Cameron Black||Executive Vice President of Discovery||N/A||N/A||N/A|
|Dr. Kim A. Seth Ph.D.||Executive VP & Chief Business Officer||N/A||N/A||N/A|
Repare Therapeutics Inc., a clinical-stage precision oncology company, engages in the discovery and development of therapeutics by using its synthetic lethality approach in Canada and the United States. It uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform, to discover, validate, and build a pipeline of SL-based therapeutics that focuses on genomic instability, including DNA damage repair. The company's lead product candidate is Camonsertib (RP-3500), an oral small molecule inhibitor under Phase ½ development for the treatment of solid tumors with specific DNA damage repair-related genomic alterations. It is also developing PKMYT1 Inhibitor (RP-6306), which is under Phase ½ clinical trial for tumors with genetic alterations characterized by CCNE1 amplification; and Polymerase Theta inhibitor, a SL target associated with BRCA mutations and other genomic alterations. The company has icense and collaboration agreement with Hoffmann-La Roche Inc. and F. Hoffmann-La Roche Ltd; Bristol-Myers Squibb Company; and Ono Pharmaceutical Co. Repare Therapeutics Inc. was incorporated in 2016 and is headquartered in St-Laurent, Canada.
Repare Therapeutics Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.